Outlook Therapeutics, Inc.(OTLK)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Outlook Therapeutics, Inc. (OTLK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OTLK at 16.0/100 on a 32-signal composite quality model, placing it at rank #2,844 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of OTLK by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, PERCEPTIVE ADVISORS, MARSHALL WACE, LLP, based on the most recent SEC filings. OTLK trades on the Nasdaq exchange and files with the SEC under CIK 1649989. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OTLK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Outlook Therapeutics, Inc. directly from SEC EDGAR.
AI Quality Score
16.0/100
AI Rank
#2,844
Net Income
$-20.3M
OTLK key financials by period
Outlook Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.4M
$-62.4M
—
FY 2019
10-K
$8.1M
$-34.5M
—
FY 2018
10-K
$3.1M
$-30.1M
—
FY 2017
10-K
$3.8M
$-38.8M
—
FY 2016
10-K
$3.0M
$-53.3M
—
FY 2015
10-K
$5.2M
$-47.4M
—
Institutions holding OTLK
Institutional investors reporting a position in Outlook Therapeutics, Inc. on SEC Form 13F.
